SAB Biotherapeutics, Inc., (SABS): Price and Financial Metrics
GET POWR RATINGS... FREE!
SABS Stock Summary
- With a one year PEG ratio of 0.47, SAB BIOTHERAPEUTICS INC is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than just 4.24% of US stocks.
- As for revenue growth, note that SABS's revenue has grown -46.12% over the past 12 months; that beats the revenue growth of just 4.25% of US companies in our set.
- SAB BIOTHERAPEUTICS INC's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -99.54%, greater than the shareholder yield of merely 5.65% of stocks in our set.
- Stocks that are quantitatively similar to SABS, based on their financial statements, market capitalization, and price volatility, are IKT, BGRY, IMV, DRRX, and EVGN.
- To dig deeper into the stock's financial statements, go to SABS's page on browse-edgar?action=getcompany&CIK=0001833214.
SABS Valuation Summary
- In comparison to the median Healthcare stock, SABS's price/sales ratio is 51.22% lower, now standing at 1.
- Over the past 25 months, SABS's EV/EBIT ratio has gone down 7.8.
Below are key valuation metrics over time for SABS.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| SABS | 2023-01-20 | 1.0 | 1 | -1.4 | -1.3 |
| SABS | 2023-01-19 | 0.9 | 1 | -1.4 | -1.3 |
| SABS | 2023-01-18 | 1.0 | 1 | -1.4 | -1.3 |
| SABS | 2023-01-17 | 1.0 | 1 | -1.4 | -1.3 |
| SABS | 2023-01-13 | 1.0 | 1 | -1.4 | -1.3 |
| SABS | 2023-01-12 | 1.0 | 1 | -1.4 | -1.3 |
SABS Stock Price Chart Interactive Chart >
SABS Price/Volume Stats
| Current price | $0.68 | 52-week high | $6.00 |
| Prev. close | $0.68 | 52-week low | $0.50 |
| Day low | $0.68 | Volume | 70,216 |
| Day high | $0.75 | Avg. volume | 57,676 |
| 50-day MA | $0.83 | Dividend yield | N/A |
| 200-day MA | $1.20 | Market Cap | 29.24M |
SAB Biotherapeutics, Inc., (SABS) Company Bio
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. The company uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors. Its lead product candidates include SAB-185, a fully-human polyclonal antibody therapeutic for the treatment of COVID-19 advancing as part of the NIH's ACTIV-2 protocol; and SAB-176, a fully-human polyclonal antibody therapeutic candidate designed to bind to type A and B viruses. The company's pre-clinical product candidates in development for autoimmune diseases include SAB-142 for type 1 diabetes and organ transplant induction/rejection; and SAB-181 for immune globulin (IgG) mediated diseases. It focuses on infectious diseases, such as COVID-19 and influenza, immune system disorders comprising type 1 diabetes, organ transplantation, and cancer. The company was founded in 2014 and is based in Miami Beach, Florida.
Latest SABS News From Around the Web
Below are the latest news stories about SAB BIOTHERAPEUTICS INC that investors may wish to consider to help them evaluate SABS as an investment opportunity.
SAB Biotherapeutics CEO Eddie Sullivan, PhD, to Present Next Generation Biologics in Immunology at BIO CEO & Investor ConferenceConference to take place Feb. 6-9 in New YorkSIOUX FALLS, S.D., Jan. 19, 2023 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, high-avidity, fully-human polyclonal antibodies without the need for human donors, announced today that Eddie Sullivan, PhD, co-founder, President and CEO of SAB Biotherapeutics, will present at the 2023 BIO CEO & Investor Conference on |
SAB Biotherapeutics Gets Another $8.2 million from Department of Defense in Closeout SettlementBy Exec Edge Editorial Staff Immunotherapy-focused SAB Biotherapeutics, Inc. (Nasdaq: SABS) announced today that the company has received an additional $8.2 million from the U.S. Department of Defense (DoD) related to the closeout of the discontinued COVID-19 prototype research and development contract. The total settlement value has now reached $16.8 million received since November 2022 […] |
SAB Biotherapeutics Receives an Additional $8.2 Million in Closeout of DoD ContractSIOUX FALLS, S.D., Jan. 18, 2023 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, high-avidity, fully-human polyclonal antibodies without the need for human donors, announced today that the company has received an additional $8.2 million from the U.S. Department of Defense (DoD) related to the closeout of the discontinued COVID-19 prototype research and develop |
SAB Biotherapeutics Successfully Concludes IND-Enabling GLP Toxicology Study for SAB-142, a Novel Immunotherapeutic for Type 1 DiabetesStudy shows SAB’s fully-human polyclonal therapeutic that has potential to delay the onset or progression of type 1 diabetes is well tolerated; next step is investigational new drug (IND) filingSIOUX FALLS, S.D., Jan. 10, 2023 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), ("SAB”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, high-avidity, fully-human polyclonal antibodies (hpAB) without the need for hu |
SAB Biotherapeutics’ CMO Alexandra Kropotova to Deliver Presentation on Next Generation Biologics in Immunology at Biotech ShowcaseSIOUX FALLS, S.D., Jan. 09, 2023 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, high-avidity, fully-human polyclonal antibodies without the need for human donors, announced today that Alexandra Kropotova, MD, Executive Vice President and Chief Medical Officer, will deliver a presentation at the Biotech Showcase in San Francisco on Tuesday, Jan. 10 at 2:30 p.m |
SABS Price Returns
| 1-mo | 15.27% |
| 3-mo | -28.43% |
| 6-mo | -43.33% |
| 1-year | -88.30% |
| 3-year | 10,361.54% |
| 5-year | N/A |
| YTD | 15.27% |
| 2022 | -92.45% |
| 2021 | N/A |
| 2020 | 0.00% |
| 2019 | -83.75% |
| 2018 | -42.86% |
Loading social stream, please wait...